Xu Chenxin, Xu Xin, Huang Yiwen, Shang Shuang, Ma Lifang
Department of Clinical Laboratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; College of Health Science and Technology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Department of Clinical Laboratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; Shanghai Institute of Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
Biochim Biophys Acta Rev Cancer. 2025 Jul;1880(3):189337. doi: 10.1016/j.bbcan.2025.189337. Epub 2025 Apr 30.
RNA methylation is a vital epigenetic modification that regulates gene expression by influencing RNA processes such as transcription, degradation, translation, and transport. Aberrant methylation, including modifications like mA, mC, mA, mG, and mC, is closely linked to tumorigenesis and progression. Liquid biopsy, a non-invasive technique analyzing tumor markers in body fluids, offers significant potential for early diagnosis and dynamic monitoring. In this context, RNA methylation, due to its tumor-specific properties, is emerging as a valuable marker. However, significant challenges remain in its clinical application. This review explores the roles of RNA methylation in cancer, recent advances in detection technologies, and its potential as a liquid biopsy marker in tumor management. It highlights its promising applications in cancer diagnosis, prognosis, and personalized treatment in the era of precision oncology.
RNA甲基化是一种重要的表观遗传修饰，通过影响转录、降解、翻译和运输等RNA过程来调节基因表达。异常甲基化，包括如mA、mC、mA、mG和mC等修饰，与肿瘤发生和进展密切相关。液体活检是一种分析体液中肿瘤标志物的非侵入性技术，在早期诊断和动态监测方面具有巨大潜力。在这种背景下，由于其肿瘤特异性特性，RNA甲基化正成为一种有价值的标志物。然而，其临床应用仍面临重大挑战。本综述探讨了RNA甲基化在癌症中的作用、检测技术的最新进展及其作为肿瘤管理中液体活检标志物的潜力。它强调了其在精准肿瘤学时代癌症诊断、预后和个性化治疗中的应用前景。
